8,784 Shares in Pfizer Inc. (NYSE:PFE) Bought by Rossby Financial LCC

Rossby Financial LCC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 8,784 shares of the biopharmaceutical company’s stock, valued at approximately $233,000.

A number of other hedge funds and other institutional investors have also modified their holdings of PFE. Norges Bank acquired a new position in shares of Pfizer in the fourth quarter worth about $2,328,986,000. Charles Schwab Investment Management Inc. boosted its stake in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock worth $4,124,330,000 after purchasing an additional 25,315,159 shares during the period. Raymond James Financial Inc. purchased a new position in Pfizer during the 4th quarter worth approximately $274,694,000. Massachusetts Financial Services Co. MA raised its stake in Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after purchasing an additional 5,350,381 shares during the period. Finally, APG Asset Management N.V. lifted its holdings in shares of Pfizer by 1,106.0% in the fourth quarter. APG Asset Management N.V. now owns 5,619,213 shares of the biopharmaceutical company’s stock valued at $143,967,000 after purchasing an additional 5,153,257 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Up 0.9 %

PFE stock opened at $22.10 on Tuesday. The stock has a market capitalization of $125.34 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The company has a 50-day moving average of $25.16 and a two-hundred day moving average of $26.33. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PFE. UBS Group lowered their price target on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a report on Tuesday, April 8th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.